+

WO1997014808A3 - Vecteurs du virus herpetique et leurs utilisations - Google Patents

Vecteurs du virus herpetique et leurs utilisations Download PDF

Info

Publication number
WO1997014808A3
WO1997014808A3 PCT/GB1996/002576 GB9602576W WO9714808A3 WO 1997014808 A3 WO1997014808 A3 WO 1997014808A3 GB 9602576 W GB9602576 W GB 9602576W WO 9714808 A3 WO9714808 A3 WO 9714808A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
malignant
cell
genetic material
human
Prior art date
Application number
PCT/GB1996/002576
Other languages
English (en)
Other versions
WO1997014808A2 (fr
Inventor
Michael Edward Griff Boursnell
Malcolm Keith Brenner
Dagmar Dilloo
Stephen Charles Inglis
Original Assignee
St Jude Childrens Res Hospital
Cantab Pharma Res
Boursnell Michael E G
Malcolm Keith Brenner
Dagmar Dilloo
Stephen Charles Inglis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9525906.5A external-priority patent/GB9525906D0/en
Application filed by St Jude Childrens Res Hospital, Cantab Pharma Res, Boursnell Michael E G, Malcolm Keith Brenner, Dagmar Dilloo, Stephen Charles Inglis filed Critical St Jude Childrens Res Hospital
Priority to EP96935051A priority Critical patent/EP0856062A2/fr
Priority to JP9515631A priority patent/JPH11513565A/ja
Priority to AU73151/96A priority patent/AU7315196A/en
Publication of WO1997014808A2 publication Critical patent/WO1997014808A2/fr
Publication of WO1997014808A3 publication Critical patent/WO1997014808A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un procédé de traitement d'une cellule humaine ou animale, visant à introduire un matériel génétique hétérologue dans ladite cellule et à exprimer ledit matériel dans ladite cellule, consiste à: a) produire un vecteur du virus herpétique recombiné, lequel est un virus herpétique mutant non transformant atténué ou à déficience de réplication, et porteur d'un matériel génétique hétérologue, et b) transduire des cellules humaines ou animales, sélectionnées à partir de: cellules hématopoïétiques, cellules malignes associées à des cellules sanguines et cellules CD34+ malignes ou non malignes; par mise en contact desdites cellules avec ledit vecteur du virus afin de transduire lesdites cellules et d'exprimer ledit matériel génétique. Parmi les applications de cette technique, on peut citer la modification des cellules hématopoïétiques par transfert de gènes, en vue, par exemple, de générer des immunogènes de tumeur à partir de cellules malignes.
PCT/GB1996/002576 1995-10-19 1996-10-21 Vecteurs du virus herpetique et leurs utilisations WO1997014808A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP96935051A EP0856062A2 (fr) 1995-10-19 1996-10-21 Vecteurs du virus herpetique et leurs utilisations
JP9515631A JPH11513565A (ja) 1995-10-19 1996-10-21 ヘルペスウィルスベクター及びその利用
AU73151/96A AU7315196A (en) 1995-10-19 1996-10-21 Herpesvirus vectors and their uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US564995P 1995-10-19 1995-10-19
US60/005,649 1995-10-19
GBGB9525906.5A GB9525906D0 (en) 1995-12-19 1995-12-19 Herpesvirus vectors
GB9525906.5 1995-12-19

Publications (2)

Publication Number Publication Date
WO1997014808A2 WO1997014808A2 (fr) 1997-04-24
WO1997014808A3 true WO1997014808A3 (fr) 1997-07-24

Family

ID=26308326

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/002576 WO1997014808A2 (fr) 1995-10-19 1996-10-21 Vecteurs du virus herpetique et leurs utilisations

Country Status (4)

Country Link
EP (1) EP0856062A2 (fr)
JP (1) JPH11513565A (fr)
CA (1) CA2234877A1 (fr)
WO (1) WO1997014808A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
EP1681346A4 (fr) * 2003-08-29 2006-11-02 Soiken Inc Vecteur de virus recombinant issu de hhv-6 ou de hhv-7, son procede de production, procede visant a transformer une cellule hote a l'aide de celui-ci, cellule hote transformee par celui-ci et procede de therapie genique l'utilisant
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US20070003520A1 (en) 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
GB2421025A (en) * 2004-12-09 2006-06-14 Oxxon Therapeutics Ltd HSV vaccination vectors
US8257712B2 (en) * 2008-07-03 2012-09-04 Saint Louis University Virus-expressing host costimulation molecules

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002788A1 (fr) * 1989-08-15 1991-03-07 British Technology Group Plc Mutant du virus de l'herpes simplex de type 1
WO1992005263A1 (fr) * 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Vaccin viral mutant a genome deficient et produit en transcomplementant la lignee cellulaire
WO1994003207A1 (fr) * 1992-07-31 1994-02-17 President And Fellows Of Harvard College Vaccin contre l'herpesvirus
WO1994021807A2 (fr) * 1993-03-19 1994-09-29 Cantab Pharmaceuticals Research Limited Virus mutant defectueux non retroviral (par ex. hsv) utilise comme vaccin
WO1995018852A1 (fr) * 1994-01-10 1995-07-13 President And Fellows Of Harvard College Mutants d'herpes virus incapables de se repliquer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002788A1 (fr) * 1989-08-15 1991-03-07 British Technology Group Plc Mutant du virus de l'herpes simplex de type 1
WO1992005263A1 (fr) * 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Vaccin viral mutant a genome deficient et produit en transcomplementant la lignee cellulaire
WO1994003207A1 (fr) * 1992-07-31 1994-02-17 President And Fellows Of Harvard College Vaccin contre l'herpesvirus
WO1994021807A2 (fr) * 1993-03-19 1994-09-29 Cantab Pharmaceuticals Research Limited Virus mutant defectueux non retroviral (par ex. hsv) utilise comme vaccin
WO1995018852A1 (fr) * 1994-01-10 1995-07-13 President And Fellows Of Harvard College Mutants d'herpes virus incapables de se repliquer

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
A. CHAUBAL ET AL.: "cd34 IMMUNOREACTIVITY IN NERVOUS SYSTEM TUMORS", ACTA NEUROPATHOL., vol. 88, 1994, pages 454 - 458, XP002030671 *
A. MIYANOHARA ET AL.: "Direct gene transfer to the liver with HSV-1 vectors: tranfer production pf physiologically relevant levels of circulating factor IX", THE NEW BIOLOGIST, vol. 4, no. 3, 1992, pages 238 - 246, XP000650666 *
B. MEIGNIER AND B. ROIZMAN: "Genetic engineering and properties of novel HSV for use as potential vaccines and as vectors of foreign genes", ADV. EXP. MED. BIOL., vol. 257, 1989, pages 187 - 192, XP000650651 *
E.A. MESRI ET AL.: "Expression of VEGF from a defective HSV-1 amplicon vector induces angiogenesis in mice", CIRCULATION RESEARCH, vol. 76, no. 2, 1995, pages 161 - 167, XP000650645 *
GUOSHENG LIN ET AL.: "Expression of CD34 in endothelial cells, hematopoietic progenitors and nervous cells in fetal and adult mouse tissues", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 25, 1995, pages 1508 - 1516, XP000653027 *
J. HUARD ET AL.: "HSV-1 vector mediated gene transfer to muscle", GENE THERAPY, vol. 2, 1995, pages 385 - 392Ÿ, XP000650866 *
J.C. MESTER ET AL.: "Antiviral activity of HSV vectors expressing murine alfa1-interferon", GENE THERAPY, vol. 2, 1995, pages 187 - 196, XP000650871 *
J.M. MONIHAN ET AL.: "CD34 immunoexpression in stromal tumors of the gastrointestinal tract and in mesenteric fibromatoses", HISTOPATHOLOGY, vol. 25, 1994, pages 469 - 473, XP002030672 *
M. VAN ZIYL ET AL.: "Live attenuated pseudorabies virus expresing enveloppe glycoprotein E1 of hog cholera virus protects swine against both pseudorabies and hog cholera", JOURNAL OF VIROLOGY, vol. 65, no. 5, 1991, pages 2761 - 2765, XP000650705 *
S. EFSTATHIOU AND A.C. MINSON: "Herpes virus-based vectors", BRITISH MEDICAL BULLETIN, vol. 51, no. 1, 1995, pages 45 - 55, XP000650614 *
S. KIT ET AL.: "Expression of porcine pseudorabies virus genes by a bovine HSV-1 (infectious bovine rhinotracheitis virus) vector", ACTA VIROL., vol. 124, 1992, pages 1 - 20, XP000650904 *
T. FRIEDMANN ET AL.: "Improved replication-defective HSV-1 vectors", J. CELL. BIOCHEM. SUPPL 0 (17 PART E), 1993, pages 220, XP000650593 *

Also Published As

Publication number Publication date
WO1997014808A2 (fr) 1997-04-24
MX9802999A (es) 1998-09-30
JPH11513565A (ja) 1999-11-24
CA2234877A1 (fr) 1997-04-24
EP0856062A2 (fr) 1998-08-05

Similar Documents

Publication Publication Date Title
ATE206463T1 (de) Virale vektoren für die gentherapie
CA2104396A1 (fr) Particules virales ayant une specificite d'hote modifiee
EP0732397A3 (fr) Hepatocytes modifiés et leur emplois
JPS57134500A (en) Plasmid pcg1
EP1923467A3 (fr) Vecteurs d'adénovirus pour thérapie génétique
CA2054517A1 (fr) Vecteurs viraux recombinants associes a un adenovirus
EP0839054A4 (fr) Replication du virus de l'herpes simplex specifique de cellule ou de tumeur
JPS57159489A (en) Developement of polypeptide in yeast
AU2853395A (en) Recombinant vectors derived from adenovirus for use in gene therapy
AU5443890A (en) Improvements in or relating to enhancers
WO1995006743A3 (fr) Procedes et compositions de production a grande echelle de virus adeno-associe recombine
GB8717430D0 (en) Recombinant dna product
AU560340B2 (en) Rennin from recombinant dna
AU2812484A (en) Dna vectors and there use in recombinant dna technology
EP0325474A3 (en) Receptor protein for human b cell stimulating factor-2
ES2013324A6 (es) Un metodo mejorado para producir una proteina heterologa.
EP0766569A4 (fr) Capsides de virus adeno-associe utilises comme vecteurs pour le transfert moleculaire
EP0480480A3 (en) Enhanced yeast transcription employing hybrid promoter region constructs
CA2321964A1 (fr) Constructions de chromosomes artificiels, contenant des sequences d'acides nucleiques capables de diriger la formation d'un virus recombine
WO1997014808A3 (fr) Vecteurs du virus herpetique et leurs utilisations
PT1021553E (pt) Cassette de expressao eucariotica de genes e suas utilizacoes
AU5318496A (en) Adenovirus vectors for gene therapy
EP0174444A3 (en) Hepatitis surface antigen particle vaccine
GR3029565T3 (en) Combined use of two expression cassettes for the production of a useful protein
NZ332555A (en) Gene expression in monocytes and macrophages associated with the CD68 gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2234877

Country of ref document: CA

Ref country code: CA

Ref document number: 2234877

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/002999

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 515631

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996935051

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996935051

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996935051

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载